Technical Analysis for AKTX - Akari Therapeutics Plc

Grade Last Price % Change Price Change
F 2.00 1.52% 0.03
AKTX closed up 1.52 percent on Monday, March 18, 2024, on 21 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
0 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down

Date Alert Name Type % Chg
Boomer Sell Setup Bearish Swing Setup 0.00%
NR7 Range Contraction 0.00%
Narrow Range Bar Range Contraction 0.00%
Lower Bollinger Band Walk Weakness 0.00%
Inside Day Range Contraction 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
New 52 Week Closing Low Bearish 1.52%
Lower Bollinger Band Walk Weakness 1.52%
Inside Day Range Contraction 1.52%

   Recent Intraday Alerts

Alert Time
Possible NR7 about 9 hours ago
Possible Inside Day about 9 hours ago
Rose Above Lower Bollinger Band about 12 hours ago
Up 1% about 12 hours ago
Possible Inside Day 3 days ago

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Akari Therapeutics Plc Description

Akari Therapeutics, Plc is a clinical-stage biopharmaceutical company that focuses on the development and commercialization of therapeutics to treat rare and orphan autoimmune and inflammatory diseases. The company develops Coversin, a second-generation complement inhibitor that acts on complement component-C5, preventing release of C5a and formation of C5b – 9 (membrane attack complex or MAC). It develops products to treat rare diseases, such as paroxysmal nocturnal haemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), myasthenia gravis (MG), Guillain Barré syndrome (GBS), and Sjögren's syndrome. The company was formerly known as Volution Immuno Pharmaceuticals SA and changed its name to Akari Therapeutics, Plc in September 2015. The company is based in New York, New York. Akari Therapeutics, Plc operates as a subsidiary of RPC Pharma Limited.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Organ Systems Rare Diseases Inflammatory Diseases Autoimmunity Autoimmune And Inflammatory Disease Complement System Myasthenia Gravis Myasthenia Acquired Hemolytic Anemia Hemoglobinuria Paroxysmal Nocturnal Hemoglobinuria C5a Hemolytic Uremic Syndrome Sjögren's Syndrome

Is AKTX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 5.546
52 Week Low 1.95
Average Volume 8,775
200-Day Moving Average 3.27
50-Day Moving Average 2.48
20-Day Moving Average 2.22
10-Day Moving Average 2.13
Average True Range 0.15
RSI (14) 31.97
ADX 35.98
+DI 10.64
-DI 27.46
Chandelier Exit (Long, 3 ATRs) 2.00
Chandelier Exit (Short, 3 ATRs) 2.39
Upper Bollinger Bands 2.45
Lower Bollinger Band 1.98
Percent B (%b) 0.04
BandWidth 20.99
MACD Line -0.13
MACD Signal Line -0.12
MACD Histogram -0.0101
Fundamentals Value
Market Cap 11.31 Million
Num Shares 5.65 Million
EPS -2.52
Price-to-Earnings (P/E) Ratio -0.79
Price-to-Sales 0.00
Price-to-Book 4.88
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.04
Resistance 3 (R3) 2.04 2.02 2.04
Resistance 2 (R2) 2.02 2.01 2.02 2.03
Resistance 1 (R1) 2.01 2.00 2.00 2.01 2.03
Pivot Point 1.99 1.99 1.98 1.99 1.99
Support 1 (S1) 1.98 1.98 1.97 1.98 1.97
Support 2 (S2) 1.96 1.97 1.96 1.96
Support 3 (S3) 1.95 1.96 1.96
Support 4 (S4) 1.95